Work

Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7568

Authors: Stefan K. Barta, Jasmine M. Zain, Sonali M. Smith, Jia Ruan, Henry C. Fung, Carlyn R Tan, Yibin Yang, R. Katherine Alpaugh, Eric A. Ross, Kerry S. Campbell, Nadia Khan, Richard I. Fisher, Yasuhiro Oki

Institutions: Fox Chase Cancer Center, City Of Hope National Medical Center, University of Chicago, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890542895

Cites:

Cited by: 19

Related to: 10